| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2003-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40e35248612a1c58c2389282280b4e5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ce37418c04da3619b34411e6cde4647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e3893c4216fd3286afbc6435cbd9e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ef249c222903444dbb386a23247a6b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f7437f78c864907b5d1be807fe5bd3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_070f5d99cdb52100aec2f74d0799dae9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6685f630499e455f17d273203c4508 |
| publicationDate |
2004-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004224031-A1 |
| titleOfInvention |
Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus |
| abstract |
Combinations comprising vanadium (IV)/(V) compounds and pharmaceutically acceptable amines selected from the group of semicarbazide-sensitive amine oxidase (SSAO) substrates are insulin mimickers. Preferred vanadium (IV)/(V) compounds are vanadyl salts, vanadyl complexes and vanadates (e.g. sodium orthovanadate). Preferred amines are tyramine and benzylamine. A here-discovered synergism between the vanadium compound and the amine makes the effective concentration of vanadate in the combination one order of magnitude lower than the corresponding of vanadate alone. Consequently the combination has much lower toxicity than the known vanadium compound alone, which is a crucial advantage of the former for its use in the treatment and/or prevention of Diabetes mellitus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012131689-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006061140-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008227809-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008524169-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005180956-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007066682-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008070987-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1669079-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006165814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006061140-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006064061-A1 |
| priorityDate |
2003-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |